AU Patent

AU2007212972B2 — Novel coumarin derivative having antitumor activity

Assigned to Chugai Pharmaceutical Co Ltd · Expires 2012-03-01 · 14y expired

What this patent protects

It is intended to provide a compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof. Because of having a sufficiently high antitumor activity, this compound or its salt is useful as a remedy for cell proliferative diseases, in parti…

USPTO Abstract

It is intended to provide a compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof. Because of having a sufficiently high antitumor activity, this compound or its salt is useful as a remedy for cell proliferative diseases, in particular, cancer. It is also intended to provide a medicinal composition which contains the above-described compound or its salt as the active ingredient. [Chemical formula 1] (1) wherein X is selected from heteroaryl, etc.; Y and Y are selected from -N=, etc.; Y and Y are selected from -CH=, etc.; A is selected from sulfamide, etc.; R is selected from hydrogen, etc.; and R is selected from C alkyl, etc.

Drugs covered by this patent

Patent Metadata

Patent number
AU2007212972B2
Jurisdiction
AU
Classification
Expires
2012-03-01
Drug substance claim
No
Drug product claim
No
Assignee
Chugai Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.